Cargando…

Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions

Methemoglobin (metHb) arises from the oxidation of ferrous hemoglobin (HbFe(2+), Hb) to ferric hemoglobin (HbFe(3+), metHb), which is unable to bind gaseous ligands such as oxygen (O(2)) and carbon monoxide (CO), and binds to nitric oxide (NO) significantly slower compared to Hb. Therefore, metHb do...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Xiangming, Hickey, Richard, Rath, Antara, Palmer, Andre F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849478/
https://www.ncbi.nlm.nih.gov/pubmed/35171971
http://dx.doi.org/10.1371/journal.pone.0263782
_version_ 1784652474458570752
author Gu, Xiangming
Hickey, Richard
Rath, Antara
Palmer, Andre F.
author_facet Gu, Xiangming
Hickey, Richard
Rath, Antara
Palmer, Andre F.
author_sort Gu, Xiangming
collection PubMed
description Methemoglobin (metHb) arises from the oxidation of ferrous hemoglobin (HbFe(2+), Hb) to ferric hemoglobin (HbFe(3+), metHb), which is unable to bind gaseous ligands such as oxygen (O(2)) and carbon monoxide (CO), and binds to nitric oxide (NO) significantly slower compared to Hb. Therefore, metHb does not elicit vasoconstriction and systemic hypertension in vivo due to its extremely slow NO scavenging rate in comparison to cell-free Hb, but will induce oxidative tissue injury, demonstrating the potential of using metHb as a control material when studying the toxicity of cell-free Hb. Hence, the goal of this work was to develop a novel manufacturing strategy for production of metHb that is amenable to scale-up. In this study, small scale (e.g. 1 mL reaction volume) screening experiments were initially conducted to determine the optimal molar ratio of Hb to the oxidization agents hydrogen peroxide (H(2)O(2)) or sodium nitrite (NaNO(2)) to achieve the highest conversion of Hb into metHb. A spectral deconvolution program was employed to determine the molar fraction of various species (hemichrome, metHb, oxyHb, metHb-[Image: see text] , and NaNO(2)) in solution during the oxidation reaction. From this analysis, either a 1:1 or 1:5 molar ratio was identified as optimal molar ratios of Hb:NaNO(2) (heme basis) that yielded the highest conversion of Hb into metHb with negligible amounts of side products. Hence in order to reduce the reaction time, a 1:5 molar ratio was chosen for large scale (i.e. 1.5 L reaction volume) synthesis of bovine metHb (metbHb) and human metHb (methHb). The biophysical properties of metHb were then characterized to elucidate the potential of using the synthesized metHb as a non-O(2) carrying control material. The haptoglobin binding kinetics of metHb were found to be similar to Hb. Additionally, the synthesized metHb was stable in phosphate buffered saline (PBS, 50 mM, pH 7.4) at 4°C for approximately one week, indicating the high stability of the material.
format Online
Article
Text
id pubmed-8849478
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-88494782022-02-17 Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions Gu, Xiangming Hickey, Richard Rath, Antara Palmer, Andre F. PLoS One Research Article Methemoglobin (metHb) arises from the oxidation of ferrous hemoglobin (HbFe(2+), Hb) to ferric hemoglobin (HbFe(3+), metHb), which is unable to bind gaseous ligands such as oxygen (O(2)) and carbon monoxide (CO), and binds to nitric oxide (NO) significantly slower compared to Hb. Therefore, metHb does not elicit vasoconstriction and systemic hypertension in vivo due to its extremely slow NO scavenging rate in comparison to cell-free Hb, but will induce oxidative tissue injury, demonstrating the potential of using metHb as a control material when studying the toxicity of cell-free Hb. Hence, the goal of this work was to develop a novel manufacturing strategy for production of metHb that is amenable to scale-up. In this study, small scale (e.g. 1 mL reaction volume) screening experiments were initially conducted to determine the optimal molar ratio of Hb to the oxidization agents hydrogen peroxide (H(2)O(2)) or sodium nitrite (NaNO(2)) to achieve the highest conversion of Hb into metHb. A spectral deconvolution program was employed to determine the molar fraction of various species (hemichrome, metHb, oxyHb, metHb-[Image: see text] , and NaNO(2)) in solution during the oxidation reaction. From this analysis, either a 1:1 or 1:5 molar ratio was identified as optimal molar ratios of Hb:NaNO(2) (heme basis) that yielded the highest conversion of Hb into metHb with negligible amounts of side products. Hence in order to reduce the reaction time, a 1:5 molar ratio was chosen for large scale (i.e. 1.5 L reaction volume) synthesis of bovine metHb (metbHb) and human metHb (methHb). The biophysical properties of metHb were then characterized to elucidate the potential of using the synthesized metHb as a non-O(2) carrying control material. The haptoglobin binding kinetics of metHb were found to be similar to Hb. Additionally, the synthesized metHb was stable in phosphate buffered saline (PBS, 50 mM, pH 7.4) at 4°C for approximately one week, indicating the high stability of the material. Public Library of Science 2022-02-16 /pmc/articles/PMC8849478/ /pubmed/35171971 http://dx.doi.org/10.1371/journal.pone.0263782 Text en © 2022 Gu et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gu, Xiangming
Hickey, Richard
Rath, Antara
Palmer, Andre F.
Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions
title Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions
title_full Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions
title_fullStr Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions
title_full_unstemmed Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions
title_short Scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions
title_sort scalable manufacturing platform for the production of methemoglobin as a non-oxygen carrying control material in studies of cell-free hemoglobin solutions
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8849478/
https://www.ncbi.nlm.nih.gov/pubmed/35171971
http://dx.doi.org/10.1371/journal.pone.0263782
work_keys_str_mv AT guxiangming scalablemanufacturingplatformfortheproductionofmethemoglobinasanonoxygencarryingcontrolmaterialinstudiesofcellfreehemoglobinsolutions
AT hickeyrichard scalablemanufacturingplatformfortheproductionofmethemoglobinasanonoxygencarryingcontrolmaterialinstudiesofcellfreehemoglobinsolutions
AT rathantara scalablemanufacturingplatformfortheproductionofmethemoglobinasanonoxygencarryingcontrolmaterialinstudiesofcellfreehemoglobinsolutions
AT palmerandref scalablemanufacturingplatformfortheproductionofmethemoglobinasanonoxygencarryingcontrolmaterialinstudiesofcellfreehemoglobinsolutions